Copyright ©2005 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2005; 11(20): 3014-3019
Published online May 28, 2005. doi: 10.3748/wjg.v11.i20.3014
Current status of tumor radiogenic therapy
Feng-Ling Min, Hong Zhang, Wen-Jian Li
Feng-Ling Min, Hong Zhang, Wen-Jian Li, Institute of Modern Physics, The Chinese Academy of Sciences, Lanzhou 730000, Gansu Province, China
Feng-Ling Min, Chinese Academy of Sciences, Beijing 100039, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Feng-Ling Min, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, Gansu Province, China.
Telephone: +86-931-4969344
Received: June 16, 2004
Revised: June 17, 2004
Accepted: July 15, 2004
Published online: May 28, 2005

Although tumor gene therapy falls behind its clinical use, the combination of irradiation and gene therapy is full of promise in cancer therapy based on traditional radiotherapy, chemotherapy and surgery. We have termed it as radiogenic therapy. This review focuses on the following aspects of radiogenic therapy in recent years: improvement of gene transfer efficiency by irradiation, radiotherapy combined with cytokine gene delivery or enhancement of the immunity of tumor cells by transgene, direct stimulation by radiation to produce cytotoxic agents, increase of tumor cell radiosensitivity in gene therapy by controlling the radiosensitivity genes and adjusting the fraction dose and interval of radiation so as to achieve the optimum antitumor effect while reducing the normal tissue damage, radioprotective gene therapy enhancing radiation tumor killing effect while protecting the normal tissue and organs with transgene using transfer vectors.

Keywords: Tumor, Radiation, Gene therapy